Microbot Medical Inc. Receives Israeli Regulatory Approval for LIBERTY® System

Microbot Medical Inc. announced on May 26, 2026, that it has received regulatory approval from the Israeli Ministry of Health's AMAR Division for its LIBERTY® Endovascular Robotic System. This approval allows the company to market and commercialize the system in Israel and to obtain a Free Sale Certificate for use in additional international markets. The company is also pursuing CE Mark certification for expansion into the EU market. The LIBERTY System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, has already been adopted by multiple hospitals in the U.S. This milestone is part of Microbot Medical's strategy to expand its commercial reach globally.